Achieving an itch-free state with Upadacitinib: a post-hoc analysis of data from the Phase 2b randomized, doubleblind, placebo-controlled trial in moderate-to-severe atopic dermatitis

被引：0
|
作者：
Silverberg, J. [1 ]
Reich, K. [2 ,3 ]
Calimlim, B., III [4 ]
Gu, Y. [4 ]
Hu, X. [4 ]
Teixera, H. [4 ]
Guttman-Yassky, E. [5 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Dermatologikum Berlin, Hamburg, Germany
[3] SCIderm Res Inst, Hamburg, Germany
[4] AbbVie Inc, N Chicago, IL USA
[5] Mt Sinai Med Ctr, Icahn Sch Med, New York, NY 10029 USA
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2020年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P080
引用
收藏
页码：37 / 37
页数：1
相关论文
共 50 条
  • [1] Achieving an itch-free state with upadacitinib: a post hoc analysis of data from a phase IIb randomized, double-blind, placebo-controlled trial in moderate-to-severe atopic dermatitis
    Silverberg, J. I.
    Reich, K.
    Calimlim, B.
    Gu, Y.
    Hu, X.
    Teixeira, H.
    Guttman-Yassky, E.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E98 - E98
  • [2] UPADACITINIB EFFECT ON PRURITUS IN MODERATE-TO-SEVERE ATOPIC DERMATITIS; FROM A PHASE 2B RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    Beck, L.
    Hong, C.
    Hu, X.
    Chen, S.
    Calimlim, B.
    Teixeira, H.
    Guttman-Yassky, E.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S21 - S21
  • [3] Early response to upadacitinib in moderate-to-severe atopic dermatitis: Results from a phase 2b randomized, placebo-controlled trial
    Reich, K.
    Guttman-Yassky, E.
    Beck, L. A.
    Hu, X.
    Pangan, A. L.
    Teixeira, H. D.
    [J]. ALLERGY, 2018, 73 : 76 - 76
  • [4] The patient-reported burden of atopic dermatitis and its association with itch: Observations from the upadacitinib phase 2b randomized, placebo-controlled trial in moderate to severe atopic dermatitis
    Silverberg, Jonathan I.
    Calimlim, Brian
    Teixeira, Henrique D.
    Wu, Meijing
    Simpson, Eric L.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB77 - AB77
  • [5] Upadacitinib improved patient-reported pruritus in moderate-to-severe atopic dermatitis: results from a phase 2B randomized, placebo-controlled trial
    Hong, C. -H.
    Wu, T.
    Calimlim, B.
    Teixeira, H.
    de Bruin-Weller, M.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 10 - 10
  • [6] Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis from a phase 2b, randomized, controlled trial
    Guttman-Yassky, Emma
    Beck, Lisa A.
    Anderson, Jaclyn K.
    Hu, Xiaofei
    Gu, Yihua
    Teixeira, Henrique D.
    Silverberg, Jonathan I.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB294 - AB294
  • [7] Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial
    Guttman-Yassky, Emma
    Silverberg, Jonathan I.
    Thaci, Diamant
    Papp, Kim A.
    Staender, Sonja
    Beck, Lisa A.
    Kim, Brian S.
    Hu, Xiaofei
    Liu, Jianzhong
    Calimlim, Brian M.
    Vigna, Namita
    Crowley, Jameson T.
    Teixeira, Henrique D.
    Thyssen, Jacob P.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (12) : 2558 - 2568
  • [8] Interpretation of EASI-75 from a patient perspective - a post-hoc analysis from a phase 2b trial of dupilumab in adults with moderate-to-severe atopic dermatitis
    Poulin, Y.
    Tyring, S.
    Kimura, T.
    Andria, M.
    Ghorayeb, E.
    Eckert, L.
    Chao, J.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 142 - 142
  • [9] EASI-75 interpretation from a patient perspective - a phase 2b post-hoc analysis of dupilumab in adults with moderate-to-severe atopic dermatitis
    Poulin, Y.
    Tyring, S.
    Kimura, T.
    Andria, M.
    Ghorayeb, E.
    Eckert, L.
    Chao, J.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 70 - 70
  • [10] Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
    Zhao, Yan
    Zhang, Jianzhong
    Yang, Bin
    Li, Jingyi
    Ding, Yangfeng
    Wu, Liming
    Zhang, Litao
    Wang, Jinyan
    Zhu, Xiaohong
    Zhang, Furen
    Tao, Xiaohua
    Li, Yumei
    Zhang, Chunlei
    Li, Linfeng
    Lu, Jianyun
    Diao, Qingchun
    Lu, Qianjin
    Man, Xiaoyong
    Li, Fuqiu
    Xia, Xiujuan
    Cheng, Hao
    Jia, Yingmin
    Zhao, Guoqing
    Yan, Jinchun
    Chen, Bo
    [J]. CHINESE MEDICAL JOURNAL, 2024, 137 (02) : 200 - 208
12345